Louth cardiac tech company to create 20 jobs

A Louth cardiac tech company has announced it is to create 20 jobs over the next three years, while targeting an additional €3m in revenue, as it expands overseas. The Ardee based business will also be rebranding as Heart Rhythm International will initially target the UK, where they expect to add 30 additional hospitals and approximately 50,000 additional patients to their network before 2029. 

They will also be looking to bring their innovative cardiac care solution to Australia/ New Zealand and the US health markets in the coming years.  

Previously known as Heart Rhythm Ireland, the company operates a cloud-based cardiac rhythm management platform that supports patients as well as hospitals, clinicians and cardiac device manufacturers. Their system makes patient cardiac device information available in real time, delivering accurate, accessible and actionable data to patients and their medical teams. This improves patient outcomes by making device data more accessible, enabling timely clinical decisions and more coordinated care.

HRI’s system also provides patients with secure access to their information anytime and anywhere, making it easier to share critical data with healthcare providers in emergencies. The company is currently developing AI and predictive analytics capabilities, which are expected to further enhance the platform by supporting earlier insights and more personalised cardiac care in the future.

Heart Rhythm International already supports over 65,000 patients across Ireland, with its platform in use at more than 50 cardiac hospitals nationwide. The company provides national coverage, working with leading institutions such as the Mater Misericordiae University Hospital, Bon Secours Health System, Beaumont Hospital, Mater Private Network, University Hospital Galway, Blackrock Health, and Cork University Hospital.

HRI expects to grow its team to 30 personnel in the coming years. For more than 15 years, HRI has served as Ireland’s national electronic health record for cardiac devices, maintaining a registry of over 100,000 implant procedures and nearly one million clinical follow-up records.

Alongside its commercial expansion, HRI is actively contributing to international research and innovation projects. It is a partner in Project CARAMEL, a €12 million initiative funded under the EU Horizon Europe programme, helping to develop AI-powered predictive models for cardiovascular risk in women aged 40 to 60. HRI is also an industry partner in the new Health Frontiers Technology Innovation Centre (HF-TIC), led by Ulster University and supported by €9.1 million in PEACEPLUS funding. Both initiatives reinforce HRI’s leadership in AI-driven digital health innovation on an international scale. 

“Every 20 seconds someone receives a cardiac implant, but the systems supporting their care haven’t kept pace,” said Robert Kelly, CEO of HRI. “HRI was set up to change that, by operating at the centre of a unique eco-system, supporting patients, hospitals and clinicians and cardiac device manufacturers. Through our system, patients receive greater peace of mind and better health outcomes, while medical personnel can make better informed and more efficient decisions. Ultimately that improves patient care and helps save lives.

Read Next: Man (40s) arrested in connection with Louth hit-and-run that left garda seriously injured

“We’ve already demonstrated how we can enhance cardiac care in Ireland by supporting over 65,000 patients and working with more than 50 hospitals nationwide. Now, we’re bringing that capability overseas. A key strength of our system is that it was built on scalable, cloud-based infrastructure in partnership with IBM, allowing it to be rapidly deployed by healthcare providers anywhere in the world.”

“We’re managing our expansion step by step, focusing initially on the UK market. However we are already discussing partnerships and opportunities with healthcare providers in the US and Australia/ New Zealand. We believe there is real opportunity for HRI to grow, to support more patients and doctors overseas, while helping advance cardiac care internationally in the years ahead,” Mr. Kelly concluded.